Cargando…

A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Paul, Behrens, Nicole, Carvallo Chaigneau, Francisco R., McEligot, Heather, Agrawal, Karan, Newman, John W., Anderson, Mark, Gershwin, Laurel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830518/
https://www.ncbi.nlm.nih.gov/pubmed/27073858
http://dx.doi.org/10.1371/journal.pone.0152913
_version_ 1782426905057689600
author Walsh, Paul
Behrens, Nicole
Carvallo Chaigneau, Francisco R.
McEligot, Heather
Agrawal, Karan
Newman, John W.
Anderson, Mark
Gershwin, Laurel J.
author_facet Walsh, Paul
Behrens, Nicole
Carvallo Chaigneau, Francisco R.
McEligot, Heather
Agrawal, Karan
Newman, John W.
Anderson, Mark
Gershwin, Laurel J.
author_sort Walsh, Paul
collection PubMed
description BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to the virus. RSV is accompanied by elevated prostaglandin E(2) (PGE(2)) which is followed by neutrophil led inflammation in the lung. Ibuprofen is a prototypical non-steroidal anti-inflammatory drug that decreases PGE(2) levels by inhibiting cyclooxygenase. HYPOTHESES: We hypothesized that treatment of RSV with ibuprofen would decrease PGE(2) levels, modulate the immune response, decrease clinical illness, and decrease the histopathological lung changes in a bovine model of RSV. We further hypothesized that viral replication would be unaffected. METHODS: We performed a randomized placebo controlled trial of ibuprofen in 16 outbred Holstein calves that we infected with RSV. We measured clinical scores, cyclooxygenase, lipoxygenase and endocannabinoid products in plasma and mediastinal lymph nodes and interleukin (Il)-4, Il-13, Il-17 and interferon-γ in mediastinal lymph nodes. RSV shedding was measured daily and nasal Il-6, Il-8 and Il-17 every other day. The calves were necropsied on Day 10 post inoculation and histology performed. RESULTS: One calf in the ibuprofen group required euthanasia on Day 8 of infection for respiratory distress. Clinical scores (p<0.01) and weight gain (p = 0.08) seemed better in the ibuprofen group. Ibuprofen decreased cyclooxygenase, lipoxygenase, and cytochrome P450 products, and increased monoacylglycerols in lung lymph nodes. Ibuprofen modulated the immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-γ gene expression in mediastinal lymph nodes. Lung histology was not different between groups, and viral shedding was increased in calves randomized to ibuprofen. CONCLUSIONS: Ibuprofen decreased PGE(2), modulated the immune response, and improved clinical outcomes. However lung histopathology was not affected and viral shedding was increased.
format Online
Article
Text
id pubmed-4830518
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48305182016-04-22 A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model Walsh, Paul Behrens, Nicole Carvallo Chaigneau, Francisco R. McEligot, Heather Agrawal, Karan Newman, John W. Anderson, Mark Gershwin, Laurel J. PLoS One Research Article BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to the virus. RSV is accompanied by elevated prostaglandin E(2) (PGE(2)) which is followed by neutrophil led inflammation in the lung. Ibuprofen is a prototypical non-steroidal anti-inflammatory drug that decreases PGE(2) levels by inhibiting cyclooxygenase. HYPOTHESES: We hypothesized that treatment of RSV with ibuprofen would decrease PGE(2) levels, modulate the immune response, decrease clinical illness, and decrease the histopathological lung changes in a bovine model of RSV. We further hypothesized that viral replication would be unaffected. METHODS: We performed a randomized placebo controlled trial of ibuprofen in 16 outbred Holstein calves that we infected with RSV. We measured clinical scores, cyclooxygenase, lipoxygenase and endocannabinoid products in plasma and mediastinal lymph nodes and interleukin (Il)-4, Il-13, Il-17 and interferon-γ in mediastinal lymph nodes. RSV shedding was measured daily and nasal Il-6, Il-8 and Il-17 every other day. The calves were necropsied on Day 10 post inoculation and histology performed. RESULTS: One calf in the ibuprofen group required euthanasia on Day 8 of infection for respiratory distress. Clinical scores (p<0.01) and weight gain (p = 0.08) seemed better in the ibuprofen group. Ibuprofen decreased cyclooxygenase, lipoxygenase, and cytochrome P450 products, and increased monoacylglycerols in lung lymph nodes. Ibuprofen modulated the immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-γ gene expression in mediastinal lymph nodes. Lung histology was not different between groups, and viral shedding was increased in calves randomized to ibuprofen. CONCLUSIONS: Ibuprofen decreased PGE(2), modulated the immune response, and improved clinical outcomes. However lung histopathology was not affected and viral shedding was increased. Public Library of Science 2016-04-13 /pmc/articles/PMC4830518/ /pubmed/27073858 http://dx.doi.org/10.1371/journal.pone.0152913 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Walsh, Paul
Behrens, Nicole
Carvallo Chaigneau, Francisco R.
McEligot, Heather
Agrawal, Karan
Newman, John W.
Anderson, Mark
Gershwin, Laurel J.
A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title_full A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title_fullStr A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title_full_unstemmed A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title_short A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
title_sort randomized placebo controlled trial of ibuprofen for respiratory syncytial virus infection in a bovine model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830518/
https://www.ncbi.nlm.nih.gov/pubmed/27073858
http://dx.doi.org/10.1371/journal.pone.0152913
work_keys_str_mv AT walshpaul arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT behrensnicole arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT carvallochaigneaufranciscor arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT mceligotheather arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT agrawalkaran arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT newmanjohnw arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT andersonmark arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT gershwinlaurelj arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT walshpaul randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT behrensnicole randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT carvallochaigneaufranciscor randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT mceligotheather randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT agrawalkaran randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT newmanjohnw randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT andersonmark randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel
AT gershwinlaurelj randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel